{'fraction_non_alphanumeric': 0.025688073394495414, 'fraction_numerical': 0.007339449541284404, 'mean_word_length': 5.348837209302325, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Paracrine action of sFLT‐1 secreted by stably‐transfected Ehrlich ascites tumor cells and therapy using sFLT‐1 inhibits ascites tumor growth in vivo

Vascular endothelial growth factor (VEGF) is known to play a major role in angiogenesis. A soluble form of Flt‐1, a VEGF receptor, is potentially useful as an antagonist of VEGF, and accumulating evidence suggests the applicability of sFlt‐1 in tumor suppression. In the present study, we have developed and tested strategies targeted specifically to VEGF for the treatment of ascites formation.